NDAORALTABLET
Approved
Oct 1972
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GEOCILLIN (carbenicillin indanyl sodium) is an oral penicillin-based antibiotic approved in 1972 for treating urinary tract infections and prostatitis caused by susceptible gram-negative and gram-positive bacteria. It is a prodrug formulation of carbenicillin that provides systemic antibacterial activity via oral administration.
LOE Approaching
Limited commercial opportunity as the product approaches loss of exclusivity with minimal branded presence expected; small, stabilized team focus.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
GEOCILLIN offers minimal career growth opportunity as a legacy product approaching loss of exclusivity with no active development pipeline. Roles linked to this product are typically focused on managed decline and transition to generic manufacturing support.
Brand Manager (legacy)Field Sales (generic conversion)
Worked on GEOCILLIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.